MedTrace Logo

Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration

NCT00748371 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2017-04-12

No results posted yet for this study

Summary

Aspirin has shown to be beneficial to some patients with certain diseases such as coronary artery disease or stroke. We are investigating how aspirin works on regulating platelets and thromboxane over time at different doses. We hope to find the best dose of aspirin and/or other medications to help people who are at risk for heart attack or stroke.

Conditions

  • Platelet Aggregation

Interventions

DRUG

aspirin

40mg aspirin: one 40-mg aspirin capsule by mouth each morning + one Avicel capsule by mouth each evening

DRUG

aspirin

1300mg aspirin: one 650-mg capsule by mouth twice daily

DRUG

placebo

Placebo: one Avicel (cellulose) capsule by mouth twice daily

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • John A Oates, M.D. · Vanderbilt University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00748371 on ClinicalTrials.gov